Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. reports developments as a clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer. Recurring updates cover its chronic hepatitis delta program, including the investigational combination of tobevibart and elebsiran, and its oncology portfolio of PRO-XTEN® dual-masked T-cell engagers across solid tumor targets.
Company news also includes clinical data presentations, trial progress, financial results, equity financing activity, and strategic collaborations. Its VIR-5500 program is a PSMA-targeted PRO-XTEN® dual-masked T-cell engager for metastatic prostate cancer, and the company also describes preclinical work across infectious diseases and oncologic malignancies.
Vir Biotechnology (Nasdaq: VIR) reported second quarter 2026 revenue of $238.9 million, primarily from license and collaboration revenue tied to a $240.0 million upfront payment from its new global strategic collaboration with Astellas. Net income was $80.1 million (basic EPS $0.48), compared with a net loss of $111.0 million a year earlier.
Vir ended the quarter with approximately $1.01 billion in cash, cash equivalents and investments, up about $198.5 million, including a $75 million equity investment from Astellas and a $48.0 million pass-through payment to Sanofi. R&D expenses rose to $135.3 million, mainly reflecting a $48.0 million milestone payment to Sanofi and higher CHD manufacturing costs, while SG&A increased to $30.2 million on one-time advisory and legal fees.
Clinically, Week 96 Phase 2 SOLSTICE data in chronic hepatitis delta showed elebsiran plus tobevibart achieved undetectable HDV RNA in 88% ITT (97% last observation carried forward) and was generally well tolerated. The Phase 3 ECLIPSE registrational program is fully enrolled, with ECLIPSE 1 topline data expected in Q4 2026. Vir and Astellas also advanced VIR-5500 in metastatic prostate cancer, initiating multiple Phase 1 monotherapy and combination dose-expansion cohorts. The company expects its cash resources to fund operations into the second half of 2028.
Vir Biotechnology (Nasdaq: VIR) announced a finance leadership transition. Senior Vice President and Chief Accounting Officer Brent Sabatini has been appointed Interim Principal Financial Officer, effective July 23. Jason O’Byrne will remain with the company through August 3 to support the transition while Vir conducts a comprehensive search for its next Chief Financial Officer.
Vir Biotechnology (Nasdaq: VIR) announced it will host a conference call on Wednesday, August 5 at 4:30 p.m. ET / 1:30 p.m. PT to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The call will be accessible via the Events & Presentations page on the Vir Biotechnology website.
Summary not available.
Vir Biotechnology (Nasdaq: VIR) will present new data from the Phase 2 SOLSTICE trial in chronic hepatitis delta at the EASL Congress 2026 in Barcelona, May 27-30, 2026.
The Week 96 efficacy and safety results in hepatitis delta are featured in an oral “Best of EASL 2026” session, and a Week 48 BMI subgroup analysis is highlighted in an EASL poster tour.
Vir Biotechnology (Nasdaq: VIR) reported Q1 2026 results and a corporate update on May 6, 2026. Key items: a closed global collaboration with Astellas for VIR-5500 with first patient dosed; positive Phase 2 SOLSTICE CHD results (77% HDV RNA TND at Week 72; 88% at Week 96 subset); $809.3M cash and investments as of March 31, 2026; net loss of $125.7M in Q1; cash runway to the second half of 2028.
Additional notes: completed $172.5M follow-on offering; Phase 3 ECLIPSE topline expected Q4 2026; complete Week 96 SOLSTICE data to be presented at EASL May 27-30, 2026.
Vir Biotechnology (Nasdaq: VIR) announced that CEO Marianne De Backer will appear in a fireside chat at the Bank of America Securities 2026 Healthcare Conference on May 12, 2026 at 4:20 p.m. PT / 7:20 p.m. ET in Las Vegas.
A live webcast will be available at the company's investor site and archived for 30 days.
Vir Biotechnology (Nasdaq: VIR) will host a conference call on Wednesday, May 6, 2026 at 4:30 p.m. ET / 1:30 p.m. PT to provide a corporate update and discuss financial results for the quarter ended March 31, 2026. The call is accessible via the company's Events & Presentations web page.
Vir Biotechnology (Nasdaq: VIR) closed its global collaboration and licensing agreement with Astellas on April 16, 2026, after the Hart-Scott-Rodino waiting period expired. The deal advances VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager for metastatic prostate cancer.
Key financial terms: Vir received a $240 million upfront, a $75 million equity investment at $10.36/share, a near-term $20 million milestone, will split U.S. profit/loss 50/50, and is eligible for up to $1.37 billion in milestones plus tiered double-digit ex-U.S. royalties; certain proceeds will be shared with Sanofi.
Vir Biotechnology (Nasdaq: VIR) announced the first patient dosed in a Phase 1 dose-expansion cohort evaluating VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager for metastatic prostate cancer (NCT05997615) on April 13, 2026.
The monotherapy expansion in late-line mCRPC will test a selected Q3W 800/2000/3500 µg/kg step-up dosing after Phase 1 dose-escalation data showed a favorable safety profile and promising anti-tumor activity presented at ASCO in February 2026. Combination expansion cohorts with an ARPI are expected to dose in the coming months ahead of planned pivotal Phase 3 trials in 2027.